Bioxis Pharmaceuticals

What Bioxis Pharmaceuticals does

Bioxis Pharmaceuticals is a French medical device company that discovers, develops, produces, and commercializes regenerative products for the dermatology and medical aesthetics market. Founded by CEO Frédéric Bertaïna and headquartered in St Genis Laval near Lyon, the company operates two product platforms: Cytosial, a monophasic hyaluronic acid dermal filler built on a proprietary Double-Level Molecular Organization that delivers elevated rheological performance and long-lasting effect for anti-aging treatments, and MTI-12, an ultrapure chitosan-based Monophasic Tissular Inductor designed to regenerate neo-tissues and collagen, currently in clinical trial investigation. The company holds worldwide rights to MTI-12 for both aesthetic and therapeutic indications, and operates from ISO 13485-certified manufacturing facilities covering Dir 93/42/CEE.

The company's commercial model is built on exclusive distribution agreements with channel partners in Europe and Asia for Cytosial, complemented by a sales-led B2B motion that targets aesthetic doctors, dermatologists, and medical professionals performing non-surgical cosmetic procedures. Revenue is generated through one-time licensing of its medical device products; pricing is not publicly disclosed. MTI-12, the second product line, remains in clinical development and is not yet a revenue contributor. The company has raised approximately $2.8 million in disclosed funding (led by Juvamed in 2016) and is supported by French public investment institutions including BPI France and the Rhône-Alpes region.

The company's competitive position rests on proprietary biomaterials IP — particularly its ultrapure chitosan matrix and worldwide MTI-12 rights — and on a manufacturing base that meets European medical device regulatory standards. Its ecosystem includes academic research partnerships with CNRS, INSA Lyon, Université Claude Bernard Lyon 1, VetAgro Sup, and ANRT, as well as cluster memberships with Medicen Paris Region and Lyon Biopole. The firmographic founding year is recorded as 2010 in one source and 2013 in another; the company history timeline begins with 2013, when Bioxis was established in France and the founding CEO met with Russian and Finnish Prime Ministers during formation.

Name

Bioxis Pharmaceuticals

Legal name

BIOXIS Pharmaceuticals SAS

Website

https://bioxis.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Bioxis Pharmaceuticals is a French medical device company that develops and commercializes regenerative products for dermatology and medical aesthetics, including the Cytosial hyaluronic acid dermal filler and the MTI-12 chitosan-based tissular inductor, sold via exclusive distributors in Europe and Asia to aesthetic practitioners.

Ownership category

akta.pro rank

Product category

Aesthetic Dermatology Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Regenerative medical devices
• Hyaluronic acid dermal fillers
• Aesthetic dermatology products
• Chitosan tissue regeneration
• Monophasic tissular inductor

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Products: Revenue generated from commercialization of dermal filler products (CYTOSIAL) and the MTI-12 technology platform for aesthetic and therapeutic applications.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Bioxis Pharmaceuticals is a discovery, development, production, and commercialization company offering medical devices for the dermatology and medical aesthetics market. The company's commercial offering centers on Cytosial, a monophasic hyaluronic acid dermal filler with Double-Level Molecular Organization, sold via exclusive distribution partners in Europe and Asia. Its pipeline product, MTI-12, is a chitosan-based monophasic tissular inductor for regenerating neo-tissues and collagen, currently under clinical trial investigation.

Product overview

Bioxis Pharmaceuticals is a discovery, development, production, and commercialization company offering two core medical device products: MTI-12 (an ultrapure chitosan-based monophasic tissular inductor for tissue regeneration) and Cytosial (a monophasic hyaluronic acid dermal filler for aesthetic dermatology). MTI-12 is in clinical trial investigation phase, while Cytosial has established exclusive distribution agreements in Europe and Asia.

Differentiator

Problem solved

Functional benefit

Brands

• MTI-12: Ultra Pure Chitosan Tissular Inductor - The First Ever Monophasic Tissular Inductor technology based on proprietary chitosan matrix that regenerates neo-tissues and collagen. Currently undergoing clinical trial investigation.
• Cytosial

Products and services

• MTI-12

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• ANRT (Association Nationale de la Recherche et de la Technologie)coreStrategic or Co-development PartnerAcademic research partnership supporting the company's R&D efforts in chitosan technology and biomaterials.
• VetAgro SupcoreStrategic or Co-development PartnerAcademic partner specializing in veterinary and agricultural sciences, supporting research collaborations.
• Medicen Paris RegioncoreStrategic or Co-development PartnerHealthcare and biotechnology cluster providing ecosystem support and networking opportunities.
• CNRScoreStrategic or Co-development PartnerFrench National Centre for Scientific Research, supporting academic research collaborations.
• Université Claude Bernard Lyon 1coreStrategic or Co-development PartnerMajor research university in Lyon supporting academic partnerships and research programs.
• INSA LyoncoreStrategic or Co-development PartnerNational Institute of Applied Sciences, engineering school partner supporting R&D collaborations.
• Lyon BiopolecoreStrategic or Co-development PartnerBiotechnology cluster in Lyon supporting innovative healthcare companies.
• CCI Lyon (Chambre de Commerce et d'Industrie)minorStrategic or Co-development PartnerChamber of Commerce and Industry providing institutional support and business development services.
• Only LyonminorStrategic or Co-development PartnerLyon economic development initiative supporting companies in the region.
• i-careminorStrategic or Co-development PartnerInstitutional partner providing support services.
• Entreprise Innovante des PôlesminorStrategic or Co-development PartnerFrench clusters recognition for innovative companies.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Teoxane Laboratories: Teoxane is a Geneva-based aesthetic medicine company specializing in hyaluronic acid dermal fillers (RHA range) with proprietary cross-linking technology. Directly comparable to Bioxis's Cytosial line as a specialized HA filler rival targeting the same dermatologist/medspa channel in Europe.
• Laboratoires Vivacy: Vivacy is a French aesthetic medicine developer of hyaluronic acid-based injectable products (Stylage range) with IP-rich IPN-like cross-linking. Highly comparable as a French/European specialty filler player commercializing through aesthetic practitioners, similar in scale and category to Bioxis.
• Sinclair Pharma: Sinclair Pharma developed and commercialized several aesthetic dermatology products including hyaluronic acid fillers (Perfectha) and collagen-stimulators (Ellansé) before being acquired by Huadong. Comparable as a specialty aesthetics company with European roots commercializing in dermatology channels.
• Croma-Pharma: Austrian-based aesthetic medicine company specializing in hyaluronic acid dermal fillers (Princess/ Saypha range) and PRP kits, sold globally through distribution. Directly comparable as a European specialty filler company of similar scale and distribution-led go-to-market.

Broad incumbents

• Galderma: Galderma is a global dermatology-focused company with Restylane hyaluronic acid fillers and broader skin-health portfolio. Comparable as the dominant HA filler incumbent against whose resources Bioxis's Cytosial is positioned.
• AbbVie (Allergan Aesthetics): AbbVie acquired Allergan Aesthetics and markets the Juvéderm hyaluronic acid filler franchise and Botox, dominating the global medical aesthetics category. Provides the benchmark competitive context for any independent HA filler specialist like Bioxis.
• Merz Aesthetics: Merz Aesthetics markets Belotero hyaluronic acid fillers and Ultherapy alongside other aesthetic devices. Comparable as an established broader aesthetics incumbent whose portfolio overlaps with Bioxis's Cytosial offering.

Emerging players

• Revance Therapeutics: Revance developed DaxibotulinumtoxinA (Daxxify) and a portfolio of aesthetic injectables. Comparable as a smaller, science-led aesthetics company bringing differentiated technology to the medical aesthetics market, similar trajectory to Bioxis with MTI-12.
• Regen Lab: Regen Lab develops PRP (platelet-rich plasma) medical devices for regenerative medicine and aesthetics. Comparable as a European, smaller-scale regenerative-medicine-device company serving dermatology and orthobiologic indications adjacent to Bioxis's MTI-12 platform.
• Anteis (Genoray subsidiary): Anteis developed hyaluronic acid dermal fillers (Esthélis, Fortélis ranges) and was acquired by Genoray. Comparable as an aesthetic dermatology specialty developer that partnered/leveraged acquirer resources to scale; mirrors a credible exit/strategic-partnership template for Bioxis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/fredbertaina
• LinkedInlinkedin.com/company/bioxis-pharmaceuticals

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioxis Pharmaceuticals